Unichem Laboratories today said it has entered into a settlement pact with pharma major Eli Lilly & Company and ICOS Corporation for resolving their patent litigation regarding generic tadalafil used for treating erectile dysfunction.
The patent litigation was in the US District Court for New Jersey, Unichem said.
The company "has entered into a settlement
agreement with Eli Lilly & Company and ICOS Corporation to resolve their patent litigation in the US District Court for District of New Jersey regarding Unichem's Abbreviated New Drug Application for generic tadalafil (CialisB)," it said in a BSE filing.
Under the agreement, Unichem expects to launch its generic tadalafil product in the US on or not before March 26, 2019 under certain circumstances, the company said.
It however did not provide any details about the 'certain circumstances'.
Shares of Unichem Laboratories were trading at Rs 247.60 per scrip on BSE, up 4.54 per cent from previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
